Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Atacicept - Merck Serono

Next Previous
Drug Profile

Atacicept - Merck Serono

Alternative Names: Anti-Blys/anti-APRIL fusion protein; TACI-Ig

Latest Information Update: 20 Nov 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator ZymoGenetics
  • Developer EMD Serono; Merck Serono; ZymoGenetics
  • Class Antirheumatics; Recombinant fusion proteins
  • Mechanism of Action B cell activating factor inhibitors; Tumour necrosis factor ligand superfamily member 13 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II/III Systemic lupus erythematosus
  • Phase II IgA nephropathy
  • Discontinued Chronic lymphocytic leukaemia; Lupus nephritis; Multiple myeloma; Multiple sclerosis; Non-Hodgkin's lymphoma; Rheumatoid arthritis

Most Recent Events

  • 19 Oct 2018 Pooled safety data from 17 clinical studies presented at the 80th American College of Rheumatology and the 82nd American College of Rheumatology and the 52nd Association of Rheumatology Health Professionals Annual Scientific Meeting (ACR/ARHP-2018)
  • 19 Oct 2018 Pharmacokinetics data from murine models, phase II/III trial (APRIL-SLE) and phase IIb ADDRESS II trial in Systemic lupus erythematosus presented at the 82nd American College of Rheumatology and the 52nd Association of Rheumatology Health Professionals Annual Scientific Meeting (ACR/ARHP-2018)
  • 19 Oct 2018 Updated efficacy data from a phase IIb ADDRESS II trial in Systemic lupus erythematosus presented at the 82nd American College of Rheumatology and the 52nd Association of Rheumatology Health Professionals Annual Scientific Meeting (ACR/ARHP-2018)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Legal

Back to top